风湿免疫指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫指南

2021 APLAR临床实践指南：痛风的治疗

2021-12-20 亚太风湿病学联盟协会 Int J Rheum Dis

痛风

2021年12月，亚太风湿病学联盟协会(APLAR)发布了痛风的治疗指南。痛风是亚太地区和全世界范围内最常见的炎性关节炎，本文主要针对亚太地区痛风的诊断和治疗提供指导建议。

中文标题：

2021 APLAR临床实践指南：痛风的治疗

英文标题：

2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout

发布机构：

亚太风湿病学联盟协会

发布日期：

2021-12-20

简要介绍：

2021年12月，亚太风湿病学联盟协会(APLAR)发布了痛风的治疗指南。痛风是亚太地区和全世界范围内最常见的炎性关节炎，本文主要针对亚太地区痛风的诊断和治疗提供指导建议。

评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1191184, encodeId=f3551191184a9, content=资料不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:31:02 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189553, encodeId=c2e9118955388, content=访问资料不存在，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 01 15:59:30 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184840, encodeId=70121184840df, content=在哪里, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00571489123, createdName=1207167807, createdTime=Sun Jan 16 15:02:05 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184822, encodeId=bc3e118482217, content=资源都没有看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc435475929, createdName=ms1000000861491970, createdTime=Sun Jan 16 13:16:48 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182343, encodeId=10101182343e1, content=资源在哪儿呢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb76447649, createdName=ms3000001095981207, createdTime=Sat Jan 08 21:04:28 CST 2022, time=2022-01-08, status=1, ipAttribution=)]
    2022-02-08 ms3000000637975859

    资料不全

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1191184, encodeId=f3551191184a9, content=资料不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:31:02 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189553, encodeId=c2e9118955388, content=访问资料不存在，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 01 15:59:30 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184840, encodeId=70121184840df, content=在哪里, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00571489123, createdName=1207167807, createdTime=Sun Jan 16 15:02:05 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184822, encodeId=bc3e118482217, content=资源都没有看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc435475929, createdName=ms1000000861491970, createdTime=Sun Jan 16 13:16:48 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182343, encodeId=10101182343e1, content=资源在哪儿呢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb76447649, createdName=ms3000001095981207, createdTime=Sat Jan 08 21:04:28 CST 2022, time=2022-01-08, status=1, ipAttribution=)]
    2022-02-01 ms3000000637975859

    访问资料不存在，

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1191184, encodeId=f3551191184a9, content=资料不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:31:02 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189553, encodeId=c2e9118955388, content=访问资料不存在，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 01 15:59:30 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184840, encodeId=70121184840df, content=在哪里, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00571489123, createdName=1207167807, createdTime=Sun Jan 16 15:02:05 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184822, encodeId=bc3e118482217, content=资源都没有看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc435475929, createdName=ms1000000861491970, createdTime=Sun Jan 16 13:16:48 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182343, encodeId=10101182343e1, content=资源在哪儿呢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb76447649, createdName=ms3000001095981207, createdTime=Sat Jan 08 21:04:28 CST 2022, time=2022-01-08, status=1, ipAttribution=)]
    2022-01-16 1207167807

    在哪里

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1191184, encodeId=f3551191184a9, content=资料不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:31:02 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189553, encodeId=c2e9118955388, content=访问资料不存在，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 01 15:59:30 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184840, encodeId=70121184840df, content=在哪里, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00571489123, createdName=1207167807, createdTime=Sun Jan 16 15:02:05 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184822, encodeId=bc3e118482217, content=资源都没有看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc435475929, createdName=ms1000000861491970, createdTime=Sun Jan 16 13:16:48 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182343, encodeId=10101182343e1, content=资源在哪儿呢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb76447649, createdName=ms3000001095981207, createdTime=Sat Jan 08 21:04:28 CST 2022, time=2022-01-08, status=1, ipAttribution=)]
    2022-01-16 ms1000000861491970

    资源都没有看到

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1191184, encodeId=f3551191184a9, content=资料不全, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:31:02 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189553, encodeId=c2e9118955388, content=访问资料不存在，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 01 15:59:30 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184840, encodeId=70121184840df, content=在哪里, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00571489123, createdName=1207167807, createdTime=Sun Jan 16 15:02:05 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184822, encodeId=bc3e118482217, content=资源都没有看到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc435475929, createdName=ms1000000861491970, createdTime=Sun Jan 16 13:16:48 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182343, encodeId=10101182343e1, content=资源在哪儿呢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb76447649, createdName=ms3000001095981207, createdTime=Sat Jan 08 21:04:28 CST 2022, time=2022-01-08, status=1, ipAttribution=)]
    2022-01-08 ms3000001095981207

    资源在哪儿呢

    0

相关指南

痛风基层合理用药指南

暂未更新 · 2021-06-04

高尿酸血症和痛风病证结合诊疗指南

中国医师协会中西医结合医师分会(DSIM/CMDA,Doctor Society of integrative Medicine，Chinese Medical Doctor Association) · 2021-01-20

痛风及高尿酸血症基层诊疗指南（实践版·2019）

中华医学会(CMA,Chinese Medical Association) · 2020-06-15

2020美国风湿病学会痛风管理指南

美国风湿病学会(ACR,American College of Rheumatology) · 2020-05-11

2018 EULAR循证建议：痛风的诊断（更新版）

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2019-06-05

2018 国际意见书：恰当应用uricosurics和雷西纳德

国外风湿免疫科相关专家小组 · 2018-09-22

拓展阅读

2011 原发性痛风诊断和治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2011-06-01

2011 ACR 痛风与高尿酸血症指南

美国风湿病学会(ACR,American College of Rheumatology) · 2011-11-04

2012 ACR 痛风管理指南

美国风湿病学会(ACR,American College of Rheumatology) · 2012-10-01

2013高尿酸血症和痛风治疗中国专家共识

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2013-08-24

2013高尿酸血症和痛风治疗中国专家共识-期刊版

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2013-11-30

2014 痛风诊断与管理的多国证据推荐意见：源自文献系统回顾整合及风湿专家"3e"方案意见

国外风湿免疫科相关专家小组 · 2014-02-09